Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,245 shares of the company’s stock after selling 321 shares during the period. Kentucky Retirement Systems’ holdings in Moderna were worth $967,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its stake in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. Larson Financial Group LLC boosted its stake in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its stake in Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after buying an additional 778 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research report on Friday, February 14th. Finally, HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $60.63.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 2,664 shares of company stock worth $115,210. Company insiders own 15.20% of the company’s stock.

Moderna Trading Down 4.6 %

NASDAQ:MRNA opened at $33.90 on Tuesday. The firm has a market cap of $13.05 billion, a PE ratio of -3.65 and a beta of 1.59. The stock has a fifty day moving average price of $37.89 and a 200 day moving average price of $52.10. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.